A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) (DUAL™ II China)

March 18, 2020 updated by: Novo Nordisk A/S

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD

This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment

Study Overview

Study Type

Interventional

Enrollment (Actual)

453

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Anhui
      • Hefei, Anhui, China, 230001
        • Novo Nordisk INvestigational Site
      • Hefei, Anhui, China, 230061
        • Novo Nordisk INvestigational Site
    • Beijing
      • Beijing, Beijing, China, 100730
        • Novo Nordisk INvestigational Site
      • Beijing, Beijing, China, 100071
        • Novo Nordisk INvestigational Site
      • Beijing, Beijing, China, 100088
        • Novo Nordisk INvestigational Site
      • Beijing, Beijing, China, 100853
        • Novo Nordisk INvestigational Site
    • Chongqing
      • ChongQing, Chongqing, China, 404000
        • Novo Nordisk INvestigational Site
    • Fujian
      • Fuzhou, Fujian, China, 350001
        • Novo Nordisk INvestigational Site
    • Guangdong
      • Guangzhou, Guangdong, China, 510120
        • Novo Nordisk INvestigational Site
      • Guangzhou, Guangdong, China, 510515
        • Novo Nordisk INvestigational Site
    • Hebei
      • Hengshui, Hebei, China, 053000
        • Novo Nordisk INvestigational Site
      • Shijiazhuang, Hebei, China, 050000
        • Novo Nordisk INvestigational Site
      • Tangshan, Hebei, China, 063000
        • Novo Nordisk INvestigational Site
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150001
        • Novo Nordisk INvestigational Site
    • Hunan
      • Yueyang, Hunan, China, 414000
        • Novo Nordisk INvestigational Site
    • Inner Mongolia
      • Huhehaote, Inner Mongolia, China, 010020
        • Novo Nordisk INvestigational Site
      • Huhhot, Inner Mongolia, China, 010050
        • Novo Nordisk INvestigational Site
    • Jiangsu
      • Changzhou, Jiangsu, China, 213003
        • Novo Nordisk INvestigational Site
      • Nanjing, Jiangsu, China, 210011
        • Novo Nordisk INvestigational Site
      • Nanjing, Jiangsu, China, 210012
        • Novo Nordisk INvestigational Site
      • Nanjing, Jiangsu, China, 210029
        • Novo Nordisk INvestigational Site
      • Zhenjiang, Jiangsu, China, 212001
        • Novo Nordisk INvestigational Site
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Novo Nordisk INvestigational Site
    • Jilin
      • Changchun, Jilin, China, 130021
        • Novo Nordisk INvestigational Site
      • Changchun, Jilin, China, 130033
        • Novo Nordisk INvestigational Site
      • Siping, Jilin, China, 136000
        • Novo Nordisk INvestigational Site
    • Liaoning
      • Dalian, Liaoning, China, 116011
        • Novo Nordisk INvestigational Site
    • Ningxia
      • Yinchuan, Ningxia, China, 750004
        • Novo Nordisk INvestigational Site
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • Novo Nordisk INvestigational Site
    • Shanghai
      • Shanghai, Shanghai, China, 200240
        • Novo Nordisk INvestigational Site
      • Shanghai, Shanghai, China, 200040
        • Novo Nordisk INvestigational Site
      • Shanghai, Shanghai, China, 200072
        • Novo Nordisk INvestigational Site
      • Shanghai, Shanghai, China, 201199
        • Novo Nordisk INvestigational Site
    • Shanxi
      • Taiyuan, Shanxi, China, 030001
        • Novo Nordisk INvestigational Site
    • Tianjin
      • Tianjin, Tianjin, China, 300052
        • Novo Nordisk INvestigational Site
    • Yunnan
      • Kunming, Yunnan, China, 650101
        • Novo Nordisk INvestigational Site
      • Shatin, New Territories, Hong Kong
        • Novo Nordisk INvestigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria: Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including procedures to determine suitability for the trial - Male or female, age at least 18 years at the time of signing inform consent - Type 2 diabetes mellitus (clinically diagnosed) - HbA1c (glycosylated haemoglobin) above or equal to 7.5% by central laboratory analysis, with the aim of a median of 8.5%. When approximately 50% of the randomised subjects have an HbA1c above 8.5%, the remaining subjects randomised must have an HbA1c below or equal to 8.5% or when approximately 50% of the subjects randomised have an HbA1c below or equal to 8.5%, the remaining subjects randomised must have an HbA1c above 8.5% - Current treatment for at least 90 calendar days prior to screening with basal insulin plus metformin plus/minus α-glucosidase inhibitors, sulphonylureas, glinides or thiazolidinediones. Subjects should be on a stable dose for at least 60 calendar days prior to screening of: Basal insulin 20-50 units (U)/day (both inclusive) ( Individual fluctuations of plus/minus 5U during the 60 day period prior to the day of screening are acceptable.) on the day of screening in combination with: - Metformin (above or equal to 1500 mg or max tolerated dose) or - Metformin (above or equal to 1500 mg or max tolerated dose) and sulphonylureas (above or equal to half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and glinide (at least half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and α-glucosidase inhibitors (AGI) (at least half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and thiazolidinediones (at least half of the max approved dose according to local label) - Body mass index (BMI) above or equal to 24 kg/m^2 Exclusion Criteria: Current use of any antidiabetic drug (except for basal insulin, metformin, α-glucosidase inhibitors, sulphonylureas, glinides or thiazolidinediones) or anticipated change in concomitant medication, that in the investigator´s opinion could interfere with glucose level (e.g. systemic corticosteroids) - Treatment with glucagon like peptide -1 receptor agonists, or dipeptidyl-peptidase-4 inhibitors or insulin (except for basal insulin) within 90 days prior to Visit 1 - Impaired liver function defined as alanine aminotransferase above or equal to 2.5 times upper normal range - Impaired renal function defined as serum-creatinine above or equal to 133 μmol/L for males and above or equal to 125 μmol/L for females, or as defined according to local contraindications for metformin Screening calcitonin above or equal to 50 ng/L - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) - Cardiac disorder defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 12 months prior to screening and/or planned coronary, carotid or peripheral artery revascularisation procedures - Severe uncontrolled treated or untreated hypertension (systolic blood pressure above or equal to 180 mm Hg or diastolic blood pressure above or equal to 100 mm Hg) - Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment - History of pancreatitis (acute or chronic)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Insulin degludec/liraglutide
Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
Active Comparator: Insulin degludec
Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in HbA1c
Time Frame: Week 0, week 26
Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 26 is presented.
Week 0, week 26

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Body Weight
Time Frame: Week 0, week 26
Change in body weight from baseline (week 0) to week 26 is presented.
Week 0, week 26
Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Time Frame: Up to 26 weeks
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed hypoglycaemic episodes during 26 weeks of treatment is presented.
Up to 26 weeks
Change in Fasting Plasma Glucose (FPG)
Time Frame: Week 0, week 26
Change in FPG from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Waist Circumference
Time Frame: Week 0, week 26
Change in waist circumference from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile
Time Frame: Week 0, week 26
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in SMPG-mean Post Prandial Increments
Time Frame: Week 0, week 26
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 is presented.
Week 0, week 26
Insulin Dose
Time Frame: Week 26
The mean of actual daily total insulin dose after 26 weeks of treatment is presented.
Week 26
SMPG-9-point Profile (Individual Points in the Profile)
Time Frame: Week 26
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. SMPG-9-point profile (individual points in the profile) at week 26 is presented.
Week 26
Change in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Total Cholesterol- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Triglycerides- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Free Fatty Acids- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting free fatty acids (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting C-peptide- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting C-peptide (measured in nanomoles per liter (nmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Insulin- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting insulin (measured in picomoles per liter (pmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in Fasting Glucagon- Ratio to Baseline
Time Frame: Week 0, week 26
Change in fasting glucagon (measured in picograms per milliliter (pg/mL)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Change in HOMA-B (Beta-cell Function)- Ratio to Baseline
Time Frame: Week 0, week 26
Change in HOMA-B from baseline (week 0) to week 26 is presented as ratio to baseline.
Week 0, week 26
Participants Who Achieved HbA1c < 7.0%, ADA Target (Yes/no)
Time Frame: Week 26
Participants who achieved HbA1c < 7.0%, ADA target (yes/no) is presented.
Week 26
Participants Who Achieved HbA1c ≤ 6.5%, American Association of Clinical Endocrinologists (AACE) Target (Yes/no)
Time Frame: Week 26
Participants who achieved HbA1c ≤ 6.5%, AACE target (yes/no) is presented.
Week 26
Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero
Time Frame: Week 26
Participants who achieved HbA1c < 7.0% and change from baseline in body weight below or equal to zero is presented.
Week 26
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero
Time Frame: Week 26
Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero is presented.
Week 26
Participants Who Achieved HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Time Frame: Week 26
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c < 7.0% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Week 26
Participants Who Achieved HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Time Frame: Week 26
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Week 26
Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Time Frame: Week 26
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c < 7.0% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Week 26
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Time Frame: Week 26
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Week 26
Number of Treatment-emergent Adverse Events (TEAEs)
Time Frame: Weeks 0-27
A TEAE was defined as an adverse event with onset date on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
Weeks 0-27
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes
Time Frame: Weeks 0-27
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed hypoglycaemic episodes is presented.
Weeks 0-27
Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Time Frame: Weeks 0-27
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes is presented.
Weeks 0-27
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Time Frame: Weeks 0-27
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value < 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes is presented.
Weeks 0-27
Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition
Time Frame: Weeks 0-27
Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA definition is presented.
Weeks 0-27
Change in Physical Examination
Time Frame: Week -2, week 26
Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at week -2 and week 26 is presented.
Week -2, week 26
Eye Examination
Time Frame: Week -2, week 26
Dilated fundoscopy or fundus photography was performed by the investigator at week -2 and week 26. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week -2 and week 26 were presented.
Week -2, week 26
Change in Electrocardiogram (ECG)
Time Frame: Week -2, week 26
The ECG was assessed by the investigator at baseline (week -2) and week 26 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 26 were presented.
Week -2, week 26
Change in Pulse
Time Frame: Week 0, week 26
Change in pulse from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Time Frame: Week 0, week 26
Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Biochemical Parameter- Amylase, Lipase, Creatinine Kinase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)
Time Frame: Week 0, week 26
Change in amylase, lipase, creatinine kinase, ALT, AST, ALP from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Biochemical Parameter-calcium (Total), Albumin Corrected Calcium, Potassium, Sodium, Urea
Time Frame: Week 0, week 26
Change in calcium (total), albumin corrected calcium, potassium, sodium, urea from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Albumin
Time Frame: Week 0, week 26
Change in albumin from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Total Bilirubin
Time Frame: Week 0, week 26
Change in total bilirubin from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Creatinine
Time Frame: Week 0, week 26
Change in creatinine from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Total Protein
Time Frame: Week 0, week 26
Change in total protein from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Haematocrit
Time Frame: Week 0, week 26
Change in haematocrit from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Haemoglobin
Time Frame: Week 0, week 26
Change in haemoglobin from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Leukocytes and Thrombocytes
Time Frame: Week 0, week 26
Change in leukocytes and thrombocytes from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Erythrocytes
Time Frame: Week 0, week 26
Change in erythrocytes from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Basophils
Time Frame: Week 0, week 26
Change in basophils from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Eosinophils
Time Frame: Week 0, week 26
Change in eosinophils from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Lymphocytes
Time Frame: Week 0, week 26
Change in lymphocytes from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Monocytes
Time Frame: Week 0, week 26
Change in monocytes from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Haematological Parameter- Neutrophils
Time Frame: Week 0, week 26
Change in neutrophils from baseline (week 0) to week 26 is presented.
Week 0, week 26
Change in Calcitonin
Time Frame: Week 0, week 26
Calcitonin levels were measured and were categorised as low, normal or high. Number of participants in each category at week 0 and week 26 were presented.
Week 0, week 26
Urinalysis (Erythrocytes, Protein, Glucose and Ketones)
Time Frame: Week 0, week 26
The urinalysis was the measurements of protein, glucose, erythrocytes and ketones at week 0 and week 26 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at week 0 and week 26 are presented.
Week 0, week 26
Anti-insulin Degludec Specific Antibodies
Time Frame: Week 27
Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Week 27
Antibodies Cross-reacting to Human Insulin
Time Frame: Week 27
Serum samples were analysed for the presence of antibodies cross-reacting to human insulin. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Week 27
Total Insulin Antibodies
Time Frame: Week 27
Serum samples were analysed for the presence of total insulin antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Week 27
Occurrence of Anti-liraglutide Antibodies (Yes/no)
Time Frame: Week 27
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies at week 27 are presented.
Week 27
Occurrence of Anti-liraglutide Antibodies Cross Reacting Native Glucagon-like Peptide-1 (GLP-1)
Time Frame: Week 27
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
Week 27
Occurrence of Neutralising Liraglutide Antibodies
Time Frame: Week 27
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.
Week 27
Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1
Time Frame: Week 27
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
Week 27

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 26, 2017

Primary Completion (Actual)

March 5, 2019

Study Completion (Actual)

April 4, 2019

Study Registration Dates

First Submitted

May 24, 2017

First Submitted That Met QC Criteria

June 2, 2017

First Posted (Actual)

June 5, 2017

Study Record Updates

Last Update Posted (Actual)

March 19, 2020

Last Update Submitted That Met QC Criteria

March 18, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • NN9068-4166
  • U1111-1154-6732 (Other Identifier: World Health Organization (WHO))
  • CTR20060909 (Registry Identifier: China Drug Trials (China))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on Insulin degludec/liraglutide

3
Subscribe